Current evidence does not suggest that GLP-1 receptor agonists exacerbate Hashimotos
When unusual acylcarnitines are identified in biological fluids in patients at much higher concentrations than in healthy individuals, the chain lengths can be indicative of certain enzymic disorders in the oxidation pathway and enable recognition of the disease involved
Different GLP-1 receptor agonists have distinct administration requirements, and following the correct instructions is essential for optimal therapeutic benefit
Often, people with rhabdomyolysis experience muscle pain, dark-colored urine, and weakness, although less than 10% of patients show these characteristic signs
No severe hypoglycemia or deaths were reported, aligning retatrutides safety profile with other incretin-based therapies
Anxiety-like behaviors were observed in 3MST knockout mice 48